welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Researchers

George Dickson, PhD

Researcher
Professor of Molecular Cell Biology
Centre for Biomedical Sciences
Royal Holloway - University of London
Egham Hill
Surrey, United Kingdom

George Dickson is Professor of Molecular Cell Biology at Royal Holloway, University of London (RHUL). He has spent most of his career studying neuromuscular disease and muscle cell biology, including the first cloning of an intact dystrophin gene, the discovery of the role of cell adhesion molecules in muscle stem cell fusion, the first identification of utrophin, and the first description of exon skipping in Duchenne muscular dystrophy (DMD). He is a member of various consortiums and projects of gene therapy. He is a past President of the European Society of Gene & Cell Therapy, and a past Secretary and founder member of the British Society for Gene Therapy.

His present research includes optimisation of exon-skipping and antisense oligonucleotide formulations for DMD, inhibition of myostatin by RNA skipping and gene therapy for DMD, development of dystrophin minigenes and AAV viral vectors for treatment of DMD, direct genome correction of DMD using endonuclease-mediated genome surgery and general muscle fibre and stem cell biology.

 

Representative Publications:

Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophy

Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy

Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult mdx Mice

Advances in gene therapy for muscular dystrophies

Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles

rareRelated